[Effects of interferon and its inducers on neutrophil chemiluminescence].
In order to evaluate effects of interferon (IFN) and its inducers on neutrophil functions, neutrophil chemiluminescence (ChL) was assayed in 12 patients treated with IFN (human lymphoblastoid interferon, 3.0 X 10(6) units/day i.m. daily) or Ge-132 (2,250 mg/day p.o. daily). The peak levels of neutrophil ChL, assayed one week after the initiation of treatment, were increased in comparison to those before treatment, but one month after treatment they were decreased to pretreatment levels in spite of the daily administration of the agent. On the basis of these results, it was concluded that IFN and Ge-132 enhanced the host defence mechanism including the activation of neutrophils, which appeared at the early phase of the host reaction.
D000230:Adenocarcinoma / Q000276:immunology; D000328:Adult; D000368:Aged; D005260:Female; D005857:Germanium / Q000494:pharmacology*; D006801:Humans; D007369:Interferon Inducers / Q000494:pharmacology*; D007370:Interferon Type I / Q000494:pharmacology*; D007680:Kidney Neoplasms / Q000276:immunology; D007951:Leukemia, Myeloid / Q000276:immunology; D008163:Luminescent Measurements; D008223:Lymphoma / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology; D009504:Neutrophils / Q000276:immunology*; D009942:Organometallic Compounds / Q000494:pharmacology*; D010101:Oxygen Consumption; D010587:Phagocytosis; D011422:Propionates
D007369:Interferon Inducers; D007370:Interferon Type I; D009942:Organometallic Compounds; D011422:Propionates; D005857:Germanium; C066750:propagermanium